FDA Panel Says Columbia Labs' (CBRX) Data on Preterm Birth Gel Isn't Sufficient (WPI)
FDA panel votes 13-4 data on Columbia Labs' (Nasdaq: CBRX) is not sufficent on preterm birth gel.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex Pharma (VRTX) wins FDA panel's vote for Kalydeco in R117H mutation
- Ocwen Financial (OCN) Resumes Trading; Shares Off Lows
- Tekmira Pharma (TKMR) Commences Limited GMP Manufacture of Guinea-Variant Ebola Therapeutic
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!